J
JSN Biomedicals
JSN Biomedicals is an early-stage oncology biotechnology company based in Barcelona, founded to develop cell therapies against solid tumours. Its work centres on a screening platform called OverTurn, which screens human genes in primary T cells to identify genetic enhancements that allow CAR T cells to function inside the tumour microenvironment. Its lead programme applies this approach to CAR gamma-delta T cells for ovarian cancer.
Founded
2026
Total funds raised
—
Rounds
0
SectorsBiotech, Oncology, Cell Therapy, Immunotherapy, CAR-T
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
No names on record yet.
Global models 4
LLyell Immunopharma
United States · lyell.com ↗
Cell therapy company that genetically reprograms T cells to resist exhaustion and work inside solid tumours.
$1B+Comparable
AArsenalBio
United States · arsenalbio.com ↗
Uses CRISPR-based genetic screens in primary T cells to find enhancements for engineered CAR T therapies against solid tumours, the same approach as OverTurn.
~$630MComparable
AAdicet Bio
United States · adicetbio.com ↗
Develops engineered gamma-delta CAR T cell therapies for cancer, the same cell type as JSN's lead programme.
~$150MComparable
GGammaDelta Therapeutics
United Kingdom · gammadeltatx.com ↗
Venture-backed developer of gamma-delta T cell therapies for solid tumours; later acquired by Takeda.
~$100MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors
No investors found yet.
Funding rounds
No announced rounds on record.
News
No coverage on record yet.